[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338538-105":59,"doc-detail-338538-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dab2ip-loss-in-luminal-a-breast-cancer-leads-to-nf-b-associated-aggressive-oncogenic-phenotypes","DAB2IP loss in luminal a breast cancer leads to NF-κB-associated aggressive oncogenic phenotypes","","Despite effective treatments for estrogen receptor–positive (ER+) breast tumors, many patients experience relapse with metastasis. Mining TCGA breast cancer RNA-Seq data shows low RasGAP DAB2IP expression links to reduced relapse-free survival in Luminal A patients, with DAB2IP loss enriched in grade 2 and higher tumors. DAB2IP-low Luminal A tumors share gene programs with aggressive subtypes, promoting proliferation, metastasis, altered ER signaling, stemness, and NF-κB activation via IKK. Integrating cell-based ChIP-Seq, motif analysis, and TCGA data identifies candidate NF-κB target genes, including altered RNA processing, connecting DAB2IP loss to recurrence mechanisms in an ER+ subset.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dab2ip-loss-in-luminal-a-breast-cancer-leads-to-nf-b-associated-aggressive-oncogenic-phenotypes/338538/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dab2ip-loss-in-luminal-a-breast-cancer-leads-to-nf-b-associated-aggressive-oncogenic-phenotypes/338538.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What relationship links DAB2IP loss to outcomes in Luminal A breast cancer?","Question",{"text":112,"@type":113},"Low DAB2IP expression is associated with a significant decrease in relapse-free survival in patients with Luminal A breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Where does DAB2IP loss occur among tumor grades?",{"text":117,"@type":113},"Immunostaining indicates DAB2IP loss occurs in grade 2 tumors and higher.",{"name":119,"@type":110,"acceptedAnswer":120},"How does DAB2IP loss mechanistically connect to aggressive oncogenic phenotypes?",{"text":121,"@type":113},"Low DAB2IP expression in ER+ breast cancer cells increases proliferation, enhances stemness, and activates IKK, which drives upstream activation of NF-κB.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338538,1790854560,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","RESE AR CH  \nARTICLE  \nAuthorship note: JMS and ASB are co–senior authors.  \nConflict of interest: The authors have declared that no conflict of interest exists.  \nCopyright: © 2024, Mukherjee et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nSubmitted: April 26, 2023  \nAccepted: October 11, 2024  \nPublished: October 17, 2024  \nReference information: JCI Insight. 2024;9(23):e171705 .  \n[https://doi.org/10.1172/jci](https://doi.org/10.1172/jci). insight.171705 .  \nDAB2IP loss in luminal a breast cancer leads to NF-κB–associated aggressive oncogenic phenotypes  \nAngana Mukherjee,1,2 Rasha T. Kakati,3 Sarah Van Alsten,4 Tyler Laws,1 Aaron L. Ebbs,1 Daniel P. Hollern,5 Philip M. Spanheimer,3 Katherine A. Hoadley,6 Melissa A. Troester,4 Jeremy M. Simon,6,7,8 and Albert S. Baldwin1,9  \n1UNC Lineberger Comprehensive Cancer, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2Department of Pathology and Laboratory Medicine and 3Division of Surgical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. 4UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 5The Salk Institute, La Jolla, California, USA. 6Department of Genetics and 7UNC Neuroscience Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. 8Department of Data Science, Dana-Farber Cancer Institute and Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 9Department of Biology, University of North Carolina at Chapel Hill, North Carolina, USA.  \nDespite proven therapy options for estrogen receptor–positive (ER+) breast tumors, a substantial number of patients with ER+ breast cancer exhibit relapse with associated metastasis. Loss of expression of RasGAPs leads to poor outcomes in several cancers, including breast cancer. Mining the The Cancer Genome Atlas (TCGA) breast cancer RNA-Seq dataset revealed that low expression of the RasGAP DAB2IP was associated with a significant decrease in relapse-free survival inpatients with Luminal A breast cancer. Immunostaining demonstrated that DAB2IP loss occurred in grade 2 tumors and higher. Consistent with this, genes upregulated in DAB2IP-low Luminal A tumors were shared with more aggressive tumor subtypes and were associated with proliferation, metastasis, and altered ER signaling. Low DAB2IP expression in ER+ breast cancer cells was associated with increased proliferation, enhanced stemness phenotypes, and activation of IKK, the upstream regulator of the transcription factor NF-κB. Integrating cell-based ChIP-Seq with motif analysis and TCGA RNA-Seq data, we identified a set of candidate NF-κB target genes upregulated with loss of DAB2IP linked with several oncogenic phenotypes, including altered RNA processing. This study provides insight into mechanisms associated with aggressiveness and recurrence within a subset of the typically less aggressive Luminal A breast cancer intrinsic subtype.  \nIntroduction  \nSince the 2000s, the incidence of female breast cancer has increased by approximately 0 .5% per year (1) . In 2021, breast cancer accounted for 12% of all new yearly cancer cases, thereby becoming the most commonly diagnosed cancer among women worldwide (2) . It is estimated that approximately 43,000 breast cancer deaths will occur in the United States in 2024 (3) . Breast cancer is a collection of heterogeneous diseases, exhibiting varied responses to different clinical treatment approaches (1) . Although early diagnosis often results in a favorable outcome, clinical and molecular features vary across the intrinsic breast tumor subtypes (4) .  \nGlobal gene expression studies have established 5 breast cancer subtypes, namely Luminal A, Luminal B, Basal-like, HER2-enriched, and Claudin-low (5) . Whereas Basal-like and HER2-enriched cancer","cbCaie4jFpiHuhSp","https://ap.wps.com/l/cbCaie4jFpiHuhSp","pdf",19161815,21,"English","# Introduction\n## Breast cancer burden and ER+ relapse risk\n## Molecular subtypes and Luminal A characteristics\n## Need to understand intra-subtype biological variability","[{\"question\":\"What relationship links DAB2IP loss to outcomes in Luminal A breast cancer?\",\"answer\":\"Low DAB2IP expression is associated with a significant decrease in relapse-free survival in patients with Luminal A breast cancer.\"},{\"question\":\"Where does DAB2IP loss occur among tumor grades?\",\"answer\":\"Immunostaining indicates DAB2IP loss occurs in grade 2 tumors and higher.\"},{\"question\":\"How does DAB2IP loss mechanistically connect to aggressive oncogenic phenotypes?\",\"answer\":\"Low DAB2IP expression in ER+ breast cancer cells increases proliferation, enhances stemness, and activates IKK, which drives upstream activation of NF-κB.\"}]","DAB2IP loss in luminal a breast cancer leads to NF-κB-associated aggressive oncogenic phenotypes | PDF",1790024104,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cda2e3cc422f95c67671c34ad1e6bcac.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5a60e6aef1b54a3eddbeb031f6296d8.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b4d31d5886b6ddae11e2e4442390a0d.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14b0f3fbfc6b2d718771b0e4f5789bf4.webp",980,1311]